The short version of MC1R fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
== Awards == On 29 September 2014, President Goodluck Jonathan honoured Muhammad with the national award of the Officer of the Order of the Niger (OON) for his contributions to primary health care in Nigeria. In 2013, Muhammad won the Public Administrator of the Year Award (PAYA), organized annually by the Centre for Policy Development and Political Studies, Lagos, Nigeria. The centre said after announcing the winner that of the 10 nominees for the award, Muhammad scored 3,025 votes, representing over 50 percent of the total votes cast. He was praised for his efforts in "eradication of poliomyelitis; reduction in maternal and infant mortality; initiatives in addressing human resource challenges in the primary health care sub-sector; integration and decentralization of HIV/AIDs intervention in PHC services in over 1,500 PHC facilities." Muhammad also won the Kwame Nkrumah Leadership Award and the Africa Leadership Icon in 2014 at the 71st Conference of AASU, held at OATTU Conference Centre, in Accra, Ghana. The Kwame Nkrumah Leadership Award and Africa Leadership Icon 2014 are awarded by the All-Africa Students' Union (AASU).
=== Abortion === In January 2025, Trump reinstated the Mexico City policy ("global gag rule"), which had been rescinded by the Biden administration. Since the 1980s, this rule has been put in place during Republican administrations and rescinded during Democratic administrations. In May 2025, in a case involving telehealth prescriptions and the abortion-drug Mifepristone, the Trump administration asked the court to dismiss the case, arguing that the states involve did not have standing. This case was Missouri v. FDA brought before federal judge Matthew Kacsmaryk in the Northern District of Texas. The states involved were Missouri, Idaho, and Kansas. In June 2025, the Centers for Medicare & Medicaid Services ended the rule which required hospitals to provide emergency abortions under the Emergency Medical Treatment and Active Labor Act. In October 2025, the Food and Drug Administration approved a generic version of the abortion pill mifepristone, allowing three U.S. companies to produce it and expanding access to medication abortion. The administration has not implemented major new restrictions on medication abortion, although Health and Human Services officials announced a review of mifepristone's safety in response to pressure from opponents.
In 2012, under prosecution by the United States Department of Justice (DoJ) based on combined investigations of the Department of Health and Human Services (HHS-OIG), FDA and FBI, primarily concerning sales and marketing of the drugs Avandia, Paxil and Wellbutrin, GSK pleaded guilty to promotion of drugs for unapproved uses, failure to report safety data and kickbacks to physicians in the United States and agreed to pay a US$3 billion (£1.9bn) settlement. It was the largest health-care fraud case to date in the US and the largest settlement in the pharmaceutical industry.
The triple quadrupole mass spectrometer essentially operates under the same principle as the single quadrupole mass analyzer. Each of the two mass filters (Q1 and Q3) contains four parallel, cylindrical metal rods. Both Q1 and Q3 are controlled by direct current (dc) and radio-frequency (rf) potentials, while the collision cell, q, is only subjected to RF potential. The RF potential associated with the collision cell (q) allows all ions that were selected for to pass through it. In some instruments, the normal quadrupole collision cell has been replaced by hexapole or octopole collision cells which improve efficiency. Unlike traditional MS techniques, MS/MS techniques allow for mass analysis to occur in a sequential manner in different regions of the instruments. The TQMS follows the tandem-in-space arrangement, due to ionization, primary mass selection, collision induced dissociation (CID), mass analysis of fragments produced during CID, and detection occurring in separate segments of the instrument. Sector instruments tend to surpass the TQMS in mass resolution and mass range. However, the triple quadrupole has the advantage of being cheaper, easy to operate and highly efficient. Also, when operated in the selected reaction monitoring mode, the TQMS has superior detection sensitivity as well as quantification. The triple quadrupole allows the study of low-energy low-molecule reactions, which is useful when small molecules are being analyzed.
Sources: en.wikipedia.org
The Centers for Disease Control and Prevention described the U.S. opioid epidemic as having arrived in three waves. 2022 research indicates that since 2016, the United States has been experiencing the fourth wave of the opioid epidemic. The epidemic began with the overprescription and abuse of prescription drugs. As prescription drugs became less accessible in 2016 in response to CDC opioid prescribing guidelines, there was an increase in demand and accessibility to cheaper, illicit alternatives to opioids, such as heroin and fentanyl.
In 2009 Congress again increased the NIH budget to $31 billion in 2010. In 2017 and 2018, Congress passed laws with bipartisan support that substantially increasing appropriations for the NIH, which was 37.3 billion dollars annually in FY2018.
Pumping protons out of the mitochondria creates a proton concentration difference across the membrane and generates an electrochemical gradient. This force drives protons back into the mitochondrion through the base of an enzyme called ATP synthase. The flow of protons makes the stalk subunit rotate, causing the active site of the synthase domain to change shape and phosphorylate adenosine diphosphate—turning it into ATP.
== Mechanical characteristics == While many uses of ivory are purely ornamental in nature, it often must be carved and manipulated into different shapes to achieve the desired form. Other applications, such as ivory piano keys, introduce repeated wear and surface handling of the material. It is therefore essential to consider the mechanical properties of ivory when designing alternatives. Elephant tusks are the animal's incisors, so the composition of ivory is unsurprisingly similar to that of teeth in several other mammals. It is composed of dentine, a biomineral composite constructed from collagen fibers mineralized with hydroxyapatite. This composite lends ivory the impressive mechanical properties—high stiffness, strength, hardness, and toughness—required for its use in the animal's day-to-day activities. Ivory has a measured hardness of 35 on the Vickers scale, exceeding that of bone. It also has a flexural modulus of 14 GPa, a flexural strength of 378 MPa a fracture toughness of 2.05 MPam1/2. These measured values indicate that ivory mechanically outperforms most of its most common alternatives, including celluloid plastic and polyethylene terephthalate. Ivory's mechanical properties result from the microstructure of the dentine tissue. It is thought that the structural arrangement of mineralized collagen fibers could contribute to the checkerboard-like Schreger pattern observed in polished ivory samples. This is often used as an attribute in ivory identification.
A styptic (also spelled stiptic) is a specific type of antihemorrhagic agent that works by contracting tissue to seal injured blood vessels. Styptic pencils contain astringents. A common delivery system for this is a styptic or hemostatic pencil (not to be confused with a caustic pencil). This is a short stick of medication. Anhydrous aluminium sulfate is the main ingredient and acts as a vasoconstrictor in order to disable blood flow. The stick is applied directly to the bleeding site. The high ionic strength promotes flocculation of the blood, and the astringent chemical causes local vasoconstriction. Before safety razors were invented, a styptic pencil was a standard part of a shaving kit and was used to seal shaving cuts. Some people continue to use styptic pencils for minor skin wounds from safety or electric razors. Styptic powder is used in the veterinary trade to stop bleeding from nails that are clipped too closely. This powder is generally used on animals, such as cats, dogs, and rabbits, whose vein is found in the center of the nail.
Sources: en.wikipedia.org
The Israelites were named after their ancestor, Jacob/Israel, who was the grandson of Abraham. They were organized into 12 tribes: Reuben, Simeon, Levi, Judah, Dan, Naphtali, Gad, Asher, Issachar, Zebulun, Joseph (or Tribe of Ephraim and Tribe of Manasseh) and Benjamin. After a famine in Canaan, Jacob and his twelve sons migrated to Egypt, where each son became the eponymous progenitor of an Israelite tribe. In Egypt, the Israelites grew from a family into a nation and were enslaved by the Egyptians. They escaped under the leadership of Moses and organized themselves as a kritarchy, where they followed laws given by Moses. Afterwards, the Israelites conquered Canaan and fought with several neighbours until they established a monarchic state. This period is covered by Genesis 12 to 1 Samuel 8.
=== Marketing === Remicade is marketed by Janssen Biotech, Inc. (formerly Centocor Biotech, Inc.) in the United States, Mitsubishi Tanabe Pharma in Japan, Xian Janssen in China, and Schering-Plough (now part of Merck & Co) elsewhere.
The death penalty should be discretionary for the offences where the death sentence is mandatory – murder, drug trafficking, firearms offences and sedition – a position similar to that for the offence of kidnapping. There are strong arguments for changing the mandatory nature of capital punishment in Singapore. Judges should be given the discretion to impose the death penalty only where deemed appropriate.
== Awards and honours == The HGSA honours one eminent member annually by inviting them to present the HGSA Oration at the Annual Scientific Meeting. Additionally, one outstanding mid-career researcher is invited to deliver a presentation at the Annual Scientific Meeting to showcase their work in the Sutherland Lecture, named in honour of Prof Grant Sutherland. Each year, the membership is invited to nominate eminent retiring members to Emeritus Membership of the Society. Nominations are called for members who have contributed significantly to the running and welfare of the Society for a Service Award. HGSA Council scrutinizes and considers these nominations before awarding.
Low-certainty evidence indicates that it mitigates worsening of peripheral neuropathy and disability from disease progression. Inotersen blocks gene expression of both wild-type and mutant TTR, reducing amyloid precursor. Moderate-certainty evidence suggests that it mitigates worsening of peripheral neuropathy. Long-term efficacy and safety of inotersen use in people with mutant TTR-related amyloidosis is still be evaluated in a phase-III clinical trial as of 2021. Both diflunisal and inotersen may also mitigate declines in quality-of-life, though the evidence for this effect is unclear. For people with cardiac ATTR the effect of inotersen use is inconclusive and requires further investigation. In 2018, inotersen was approved by the European Medicines Agency to treat polyneuropathy in adults with hereditary transthyretin amyloidosis. It has since been approved for use in Canada, the European Union and in the USA. Patisiran functions similarly to inotersen. Moderate-certainty evidence suggests that patisiran mitigates worsening of peripheral neuropathy and disability from disease progression. Additionally, low-certainty evidence suggests that patisiran mitigates decreases in quality-of-life and slightly reduces the rate of adverse events versus placebo. There is no evidence of an effect on mortality rate. A review of early data from use of patisiran in people with variant cardiac ATTR suggests that it may reduce mortality and hospitalization, however this is still being investigated and requires further investigation.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.